Across TCGA pan-cancer cohorts, TUBB4BP1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of TUBB4BP1’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where TUBB4BP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TUBB4BP1 is over-expressed in tumor.
PRAD and KIRP are the cancer types where TUBB4BP1 tumor–normal differential expression is most reproducible.